Open Access
Cancer Biology & Medicine March 2024, 21 (3) 198-203; DOI: https://www.frankenthalerfoundation.org
Cancer immunotherapy has emerged as a promising approach in cancer treatment and is considered a major advancement after surgical interventions, radiotherapy, chemotherapy, and targeted therapy. The clinical use of immunotherapeutic drugs, particularly antibody-based drugs that target immune checkpoints, has notably increased[1]. Unlike traditional antitumor drugs, which exclusively targeting tumor cells, these drugs have a unique mechanism of action, as they inhibit protein-protein interactions across multiple cell types, such as PD-1/PD-L1 blockade may function to interfere among T cell, tumor cell, macrophage, and dendritic cell (Figure 1). Nevertheless, timely withdrawal of antibody therapeutics in the presence of immune-mediated adverse reactions poses a substantial challenge, because of their high molecular weight and long half-life. The cellular uptake of most small molecule chemical drugs is generally feasible but may be accompanied by off-target effects. Peptide therapeutics, in contrast, occupy an intermediate position between monoclonal antibody therapeutics and small molecule chemical drugs in the spectrum of therapeutic agents. Peptides have notable advantages, including remarkable selectivity, particularly to drug targets on the cell surface, robust infiltration into solid tumors, and facile synthesis; therefore, they are critical contenders for immune checkpoint inhibition.
Figure 1
Immune checkpoints as drug targets for cancer immunotherapy. The interaction of immune checkpoint receptors and ligands expressed on the surfaces of MDSCs, macrophages, T cells, and tumor cells are shown.
However, the clinical utility of peptide therapeutics is constrained by 2 primary obstacles: enzymatic degradation within the physiological milieu and suboptimal oral bioavailability. Various approaches have been implemented to avoid enzymatic degradation, including the use of non-natural amino acids, cyclization modification, and mirror-image phage display technology to develop peptides consisting of amino acids in all-D configuration[2],[3]. The strategic development of suitable formulations can improve the oral characteristics and bioavailability of peptides. The primary objective of this review is to provide a brief overview of advancements in peptide immune checkpoint inhibitors. In addition, the potential applications and future prospects of these peptides in cancer immunotherapy and diagnosis are examined.
Through high-throughput screening or rational design guided by the crystal structure of the PD-1/PD-L1 complex, peptide inhibitors have been designed to target PD-1/PD-L1[4]–[6]. Nevertheless, these peptides, comprising L-amino acids, have shown suboptimal stability and have encountered challenges in achieving robust target blockade. Peptide cyclization has been demonstrated to enhance the enzymatic degradation stability and conformational stability of peptides[7]. BMS-986189 (Figure 2), a macrocyclic peptide developed by Bristol-Myers Squibb (BMS), has been designed to target PD-L1. This promising therapeutic candidate has progressed to a phase I clinical trial[8]. In an alternative approach, mirror-image phage display technology enables the screening of peptides with an all-D configuration. This innovative method effectively addresses concerns regarding enzymatic degradation stability and offers a comprehensive solution. We have successfully generated a novel class of anti-proteolytic peptides denoted D PPA-1 (nyskptdrqyhf), which target PD-L1[9] and comprise exclusively all-D amino acids. Moreover, another D-peptide targeting PD-L1, OPBP-1 (Gqsehhmrvysf), has been obtained and loaded with trimethyl chitosan hydrogel for oral administration. This peptide shows notably enhanced oral bioavailability and half-life in rats. Therefore, OPBP-1 is the first peptide for oral administration for immune checkpoint blockade[10].
Beyond the PD-1/PD-L1 axis, other pairs of immune checkpoints have major roles in the context of tumor-induced immunosuppression; these pairs include the T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) and poliovirus receptor (PVR); lymphocyte activation gene 3 (LAG-3) with major histocompatibility complex class II (MHC-II); and V-domain Ig suppressor of T cell activation (VISTA) with P-selectin glycoprotein ligand 1 (PSGL-1). Concurrently inhibiting these targets is anticipated to increase the efficacy of PD-1/PD-L1 blockade.
Using mirror-image phage display, our team has successfully acquired D TBP-3 (GGytfhwhrlnp), the first D peptide inhibitor that blocks the TIGIT/PVR interaction. The remarkable efficacy of D TBP-3 has been observed in 2 distinct murine cancer models: the anti-PD-1 antibody-responsive CT26 colorectal cancer model and the anti-PD-1 antibody-resistant 4T1 breast cancer model[11]. By using phage display, we have discovered the initial cyclic peptide inhibitor C25 (CVPMTYRAC), which blocks the LAG-3/MHC-II interaction. The administration of C25 peptide notably increases both the quantity and efficacy of CD8+ T cells, but not CD4+ T cells, localized at tumor sites. Additionally, the relative abundance of Treg cells within tumor tissue decreases[12]. Given the presence of an acidic microenvironment within tumor tissues, we have identified peptide inhibitors that selectively target immune checkpoints within this acidic milieu. Pal-DVS3 (dpGWSFGKLHWPGS-Pal), a peptide inhibitor with incorporation of D-amino acids to enhance enzymatic stability and fatty acid modifications to prolong the in vivo half-life, has been specifically designed to target VISTA/PSGL-1. This peptide exhibits enduring anti-tumor effects by mitigating the immunosuppressive effects of myeloid-derived suppressor cells (MDSCs) on CD8+ T cells[13].
The intriguing phenomenon of “cold tumors”, distinguished by a lack of T cell infiltration within specific tumor tissues, is a formidable obstacle in immunotherapy. Nevertheless, most solid tumors have substantial presence of macrophages—immune cells with crucial roles in the tumor microenvironment. Interestingly, certain immune checkpoints, such as CD47/SIRPα and CD24/Siglec10, and even PD-1/PD-L1, have been identified as key players in regulating the “don’t eat me” signal. These checkpoints effectively hinder macrophage phagocytosis, thereby impeding the elimination of tumor cells by macrophages.
Our group has used phage display technology to develop peptide inhibitors targeting CD47/SIRPα. Notably, we have successfully identified pep-20, along with its terminal D-amino acid substituted analogue, pep-20-D12 (awsATWSNYwrh), as potential inhibitors. Our findings suggest that peptides without Fc-mediated ADCC effects may be superior alternatives to CD47 antibodies because these peptides can specifically activate macrophages in the tumor microenvironment rather than inducing the phagocytosis of peripheral red blood cells, thus avoiding anemia[14]. Recently, using phage display and subsequent retro-inverse strategies, we have successfully developed a D-peptide CSBP (ldvflyse) that targets both CD24/Siglec10 and PD-1/PD-L1. These peptides increase the phagocytic activity of both macrophages and M-MDSCs, thus fortifying the innate immune response. Moreover, they increase the functionality of CD8+ T cells and consequently foster adaptive anti-tumor immune responses. Particularly when used in conjunction with radiotherapy, these peptides have robust synergistic anti-tumor effects, owing to substantial infiltration of macrophages and MDSCs into tumor tissues induced by radiotherapy[15].
Other immune cells also express immune checkpoints, such as TIPE2[16] and KIR2DL4[17] on NK cells; TIM-1[18] on B cells; and gp49B[19] on neutrophils, NK cells, monocytes, etc. Although these immune checkpoints and various immune cells play a crucial immune modulatory role in the anti-tumor immune response, studies on their peptide inhibitors remain limited. Future research will greatly benefit from the development of peptides targeting these immune checkpoints.
Dual-function peptides, akin to bispecific antibodies, are peptide entities that have been conjugated to effectively target 2 functionally related or complementary entities. This unique characteristic enables them to concurrently regulate distinct signaling pathways, thereby exhibiting multifaceted modulatory effects (Figure 3). In contrast to bispecific antibodies, dual-function peptides have relatively streamlined, less complex design and synthesis processes.
Figure 3
Strategies for the design and modification of peptides. The stability of peptides can be enhanced by cyclization, stapling, or the use of non-natural amino acids. FcRn or albumin targeting designs or lipid acid modifications can extend the in vivo half-life of peptides. Rational conjugation designs can endow peptides with dual functions. Nanomaterials can be used for oral peptide delivery. Peptides can be self-assembled, coupled to create PDCs, or conjugated with radiolabels for tumor diagnosis or treatment.
In our recent study, we designed a novel peptide inhibitor known as Pal-DMPOP (Pal-PEG 4-WSMTWWNYWrvysf), by combining the minimal active fragment of the PD-1/PD-L1 blocking peptide OPBP-1 with the minimal variant of the CD47/SIRPα peptide inhibitor pep-20. Pal-DMPOP exerts its immunomodulatory effects by selectively engaging and modulating the signaling pathways associated with both T cell and macrophage checkpoints, thus leading to the activation and enhancement of anti-tumor immune responses[20]. In another study, we have conjugated the minimal active fragment of OPBP-1 with the anti-angiogenesis peptide D A7R, and subsequently coupled this bispecific peptide with the albumin-binding peptide D SP, thus yielding a long-acting dual-functional peptide termed D SPOGS. The D A7R peptide has notable anti-tumor effects through impeding neovascularization within tumor tissues. Unfortunately, these anti-angiogenic effects impede the infiltration of immune cells into tumor tissue. However, D SPOGS effectively addresses this concern and has demonstrated synergistic anti-tumor effects[21].
In contrast to antibody-drug conjugates (ADCs), peptides can be more easily conjugated with small molecule drugs, thereby facilitating straightforward synthesis. Amphiphilic PDCs have been engineered by conjugating the small molecule radiosensitizers with the PD-1/PD-L1 blocking peptide D PPA-1. The self-assembly of these molecules results in the formation of nanoparticles, which effectively encapsulate TLR7/8 agonists. This intricate process has remarkable synergistic outcomes, wherein radiotherapy sensitization, activation of innate immunity, and enhancement of adaptive immune responses are achieved concurrently[22]. In another study, the D PPA-1 peptide has been conjugated with the chemotherapeutic agent doxorubicin by using a substrate sequence specifically designed for matrix metalloproteinase 2 (MMP2). This strategic approach has led to the development of nanoparticles that are responsive to the enzymatic activity of MMP2. The nanoparticles have a dua
